The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

(1) Background: Fidaxomicin has been shown to significantly reduce <i>Clostridioides difficile</i> infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question....

Full description

Bibliographic Details
Published in:	Antibiotics
Main Authors:	Ronald G. Hall, Travis J. Cole, Chip Shaw, Carlos A. Alvarez
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Subjects:	fidaxomicin vancomycin <i>Clostridioides difficile</i> CDI recurrence
Online Access:	https://www.mdpi.com/2079-6382/11/3/295

Similar Items

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study
by: Marcos Hernando-Gozalo, et al.
Published: (2024-05-01)

Fidaxomicin for the Treatment of <i>Clostridioides difficile</i> Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
by: Daniele Roberto Giacobbe, et al.
Published: (2022-10-01)

Does Fidaxomicin reduce Cure and Recurrence rates compared to Vancomycin in Clostridium Difficile Infection patients?: A Systematic Review and Meta-analysis
by: Hiral N Golakiya, et al.
Published: (2022-06-01)

<i>Clostridioides difficile</i> infection in hospital and community settings: summary document of a multidisciplinary group
by: Anna Danise, et al.
Published: (2024-02-01)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
by: Laura Whitney, et al.
Published: (2023-01-01)

Antimicrobial Resistance of <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> in Cambodia
by: Lengsea Eng, et al.
Published: (2025-09-01)

Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
by: Chun-Wei Chiu, et al.
Published: (2021-12-01)

Updated Management Guidelines for <i>Clostridioides difficile</i> in Paediatrics
by: Margherita Gnocchi, et al.
Published: (2020-04-01)

<i>Clostridioides difficile</i> Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis
by: Alice Annalisa Medaglia, et al.
Published: (2023-04-01)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating <i>Clostridioides difficile</i> Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
by: Nobuaki Mori, et al.
Published: (2023-08-01)

Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection
by: Jasna Rahimić, et al.
Published: (2025-04-01)

Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection
by: Shaodong Wei, et al.
Published: (2022-12-01)

Is Three Company or a Crowd? Comparing and Contrasting U.S. and European <i>Clostridioides</i><i>difficile</i> Clinical Practice Guidelines
by: Jordan Jones, et al.
Published: (2022-09-01)

In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat,
by: Orna Schwartz, et al.
Published: (2025-03-01)

Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan
by: Jun Hirai, et al.
Published: (2025-02-01)

Clostridioides difficile Infection: Updates on Epidemiologic Patterns, Diagnostic Tools, and Treatment Modalities
by: Lamiaa Abd El-Fattah MADKOUR
Published: (2023-07-01)

Controversies in the Prevention and Treatment of <i>Clostridioides difficile</i> Infection in Adults: A Narrative Review
by: Taryn B. Bainum, et al.
Published: (2023-02-01)

Biofilm Formation of <i>Clostridioides difficile</i>, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI
by: Leon M. T. Dicks
Published: (2023-08-01)

Bezlotoxumab in Patients with a Primary <i>Clostridioides difficile</i> Infection: A Literature Review
by: Guido Granata, et al.
Published: (2022-10-01)

Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat Relapsing <i>Clostridioides difficile</i> Infection
by: Khalid Alyahya, et al.
Published: (2023-06-01)

Can Gut Microbiota Analysis Reveal <i>Clostridioides difficile</i> Infection? Evidence from an Italian Cohort at Disease Onset
by: Roberto Rosato, et al.
Published: (2024-12-01)

<i>Clostridioides difficile</i> in Peripartum Women: Review of Outcomes and Treatment
by: Ravina Kullar, et al.
Published: (2025-08-01)

The Role of Bezlotoxumab for the Prevention of Recurrent <i>Clostridioides difficile</i> Infections: A Review of the Current Literature and Paradigm Shift after 2021
by: Melanie L. Hyte, et al.
Published: (2022-09-01)

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD
by: L. Walsh, et al.
Published: (2024-12-01)

Clostridium difficile colitis in an immunocompromised patient treated with fidaxomicin
by: Marcello Feasi
Published: (2015-05-01)

Against <i>Clostridioides difficile</i> Infection: An Update on Vaccine Development
by: Jingyao Wang, et al.
Published: (2025-05-01)

Potential for Misinterpretation in the Laboratory Diagnosis of <i>Clostridioides difficile</i> Infections
by: Alexandra Kalacheva, et al.
Published: (2025-05-01)

<i>Clostridioides difficile</i> and Gut Microbiota: From Colonization to Infection and Treatment
by: Patrizia Spigaglia
Published: (2024-07-01)

Clostridium difficile associated diarrhea, successfully managed with custom prepared oral vancomycin
by: JAMA Jayatilake, et al.
Published: (2022-04-01)

Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019–2021
by: Chin-Shiang Tsai, et al.
Published: (2024-04-01)

Influence of Probiotics on the Development of <i>Clostridioides difficile</i> Infection in Patients Receiving Fluoroquinolones
by: Mary E. Sheffield, et al.
Published: (2021-08-01)

Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015–2020
by: Chinenye M. Okafor, et al.
Published: (2023-05-01)

National Surveillance for Clostridioides difficile Infection, Sweden, 2009–2016
by: Kristina Rizzardi, et al.
Published: (2018-09-01)

Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against <i>Clostridioides difficile</i> Infection
by: Shaohui Wang, et al.
Published: (2024-12-01)

Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors of <i>Clostridioides difficile</i>
by: Zoe Masset, et al.
Published: (2024-04-01)

<i>Clostridioides difficile</i> in Pigs and Dairy Cattle in Northern Italy: Prevalence, Characterization and Comparison between Animal and Human Strains
by: Patrizia Spigaglia, et al.
Published: (2023-07-01)

Editorial: Clostridioides difficile infection
by: Guido Granata, et al.
Published: (2024-02-01)

<i>Clostridioides difficile</i> and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
by: Kateřina Bogdanová, et al.
Published: (2021-10-01)

A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure and <i>Clostridioides difficile</i> Infection
by: Bogdan Ioan Vintila, et al.
Published: (2024-02-01)

Risks and Preventive Strategies for Clostridioides difficile Transmission to Household or Community Contacts during Transition in Healthcare Settings
by: Ramin Asgary, et al.
Published: (2021-07-01)